MARKER THERAPEUTICS, INC.: 10-Q filed 2016-11-04

Name: MARKER THERAPEUTICS, INC.: 10-Q filed 2016-11-04
Creator: MARKER THERAPEUTICS, INC.

What MARKER THERAPEUTICS, INC. reported in its quarterly report filed 2016-11-04 (fiscal Q3 2016): 15 published measures, 46 facts as tagged in accession 0001144204-16-131724.

This filing

Form: 10-Q (quarterly report)
Filed: 2016-11-04
Fiscal period: fiscal Q3 2016
Accession: 0001144204-16-131724 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MARKER THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2016-09-30	9,698,425	USD
At 2015-12-31	6,645,367	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2016-09-30	7,493,981	USD
At 2015-12-31	-21,360,356	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-2,102,962	USD	92
2016-01-01 to 2016-09-30	-878,561	USD	274
2015-07-01 to 2015-09-30	28,503,325	USD	92
2015-01-01 to 2015-09-30	-32,413,693	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2016-09-30	-144,238,988	USD
At 2015-12-31	-133,508,427	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	7,281,000	shares	92
2016-01-01 to 2016-09-30	6,370,000	shares	274
2015-07-01 to 2015-09-30	4,048,750	shares	92
2015-01-01 to 2015-09-30	3,054,297	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	7,281,000	shares	92
2016-01-01 to 2016-09-30	6,935,000	shares	274
2015-07-01 to 2015-09-30	6,745,416	shares	92
2015-01-01 to 2015-09-30	3,054,297	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-0.29	USD/shares	92
2016-01-01 to 2016-09-30	-0.14	USD/shares	274
2015-07-01 to 2015-09-30	7.04	USD/shares	92
2015-01-01 to 2015-09-30	-10.61	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-0.29	USD/shares	92
2016-01-01 to 2016-09-30	-0.54	USD/shares	274
2015-07-01 to 2015-09-30	4.23	USD/shares	92
2015-01-01 to 2015-09-30	-10.61	USD/shares	273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	1,309,109	USD	274
2015-01-01 to 2015-09-30	261,805	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-2,721,637	USD	92
2016-01-01 to 2016-09-30	-6,900,949	USD	274
2015-07-01 to 2015-09-30	-1,737,978	USD	92
2015-01-01 to 2015-09-30	-3,904,186	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2016-09-30	2,204,444	USD
At 2015-12-31	28,005,723	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	1,109,332	USD	92
2016-01-01 to 2016-09-30	3,343,248	USD	274
2015-07-01 to 2015-09-30	968,759	USD	92
2015-01-01 to 2015-09-30	2,324,432	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2016-09-30	8,395,768	shares
At 2015-12-31	5,882,976	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2016-09-30	151,724,573	USD
At 2015-12-31	112,142,187	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	1,612,305	USD	92
2016-01-01 to 2016-09-30	3,557,701	USD	274
2015-07-01 to 2015-09-30	769,219	USD	92
2015-01-01 to 2015-09-30	1,579,754	USD	273

Inspect the source

Entity: MARKER THERAPEUTICS, INC. / CIK 0001094038
Captured: 2026-09-20T05:22:11.393Z
SEC response SHA-256: 11a45295baae8ad4450041d3d51c2454c6531734b6bbb806e124ea5eb0db02da

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094038.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))